Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

Cited by (999)

Items 301–400 of 999

1. Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)
   Ute F. Röhrig, A. Reynaud, Somi Reddy Majjigapu, Pierre Vogel, Florence Pojer, Vincent Zoete · 2019 · Journal of Medicinal Chemistry
2. A Novel Cancer Therapy by Skin Delivery of Indoleamine 2,3-Dioxygenase siRNA
   Meng‐Chi Yen, Chi‐Chen Lin, Yi‐Ling Chen, Shih-Shien Huang, Huei‐Jiun Yang, Chih‐Peng Chang, Huan-Yao Lei, Ming-Derg Lai · 2009 · Clinical Cancer Research
3. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
   Ben Creelan, Scott Joseph Antonia, Gerold Bepler, Timothy J. Garrett, George R. Simon, Hatem Hussein Soliman · 2013 · OncoImmunology
4. Recent advances in clinical trials targeting the kynurenine pathway
   Ananda Staats Pires, Gayathri Sundaram, Benjamin Heng, Shivani Krishnamurthy, Bruce James Brew, Gilles J. Guillemin · 2021 · Pharmacology & Therapeutics
5. Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase
   Hélène Maby-El Hajjami, Patricia Amé-Thomas, Céline Pangault, Olivier Tribut, John De Vos, Rachel Jean, Nadège Bescher, Céline Monvoisin, Joëlle Dulong, Thierry Lamy et al. · 2009 · Cancer Research
6. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment
   Cara C. Schafer, Yong Wang, Kenneth P. Hough, Anandi Sawant, Stefan C. Grant, Victor John Thannickal, Jaroslaw W. Zmijewski, Selvarangan Ponnazhagan, Jessy S. Deshane · 2016 · Oncotarget
7. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model
   Mitsuto Hanihara, Tomoyuki Kawataki, Kyoko Oh‐oka, Kentaro Mitsuka, Atsuhito Nakao, Hiroyuki Kinouchi · 2015 · Journal of neurosurgery
8. Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy
   Munn, David H., Sharma, Madhav D., Johnson, Theodore S. · 2018 · Cancer Research
9. Different Partners, Opposite Outcomes: A New Perspective of the Immunobiology of Indoleamine 2,3-Dioxygenase
   Ciriana Orabona, Maria Teresa Pallotta, Ursula Grohmann · 2012 · Molecular Medicine
10. Reversal of the Kynurenine Pathway of Tryptophan Catabolism May Improve Depression in ART-Treated HIV-Infected Ugandans
    Priscilla Martínez, Alexander C. Tsai, Conrad K. Muzoora, Annet Kembabazi, Sheri D. Weiser, Yong Huang, Jessica Elizabeth Haberer, Jeffrey N. Martin, David R. Bangsberg, Peter W. Hunt · 2013 · JAIDS Journal of Acquired Immune Deficiency Syndromes
11. Bin1 Ablation Increases Susceptibility to Cancer during Aging, Particularly Lung Cancer
    Mee Young Chang, Janette Boulden, Jessica B. Katz, Liwei Wang, Thomas Joshua Meyer, Alejandro Peralta Soler, Alexander J. Muller, George C. Prendergast · 2007 · Cancer Research
12. Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
    Xin Liu, R. Newton, Steven Friedman, Peggy Scherle · 2009 · Current Cancer Drug Targets
13. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment
    Alessandro Isidori, Valentina Salvestrini, Marilena Ciciarello, Federica Loscocco, Giuseppe Visani, Sarah Parisi, Mariangela Lecciso, Darina Očadlíková, Lara Rossi, Elisa Gabucci et al. · 2014 · Expert Review of Hematology
14. Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non–Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling
    Mingxiang Ye, Yong Zhang, Hongjun Gao, Yan Xu, Pengyu Jing, Jianxiong Wu, Xinxin Zhang, Jie Xiong, Chenfang Dong, Libo Yao et al. · 2017 · Clinical Cancer Research
15. CLL-cell-mediated MDSC induction by exosomal miR-155 transfer is disrupted by vitamin D
    Heiko Bruns, Martin Böttcher, Mirjeta Qorraj, Mario Fabri, Simon Jitschin, Jochen Dindorf, L. Busch, Regina Jitschin, Andréas Mackensen, Dimitrios Mougiakakos · 2016 · Leukemia
16. A Review: Phytochemicals Targeting JAK/STAT Signaling and IDO Expression in Cancer
    Niroshaathevi Arumuggam, Neil A. Bhowmick, H.P. Vasantha Rupasinghe · 2015 · Phytotherapy Research
17. Immunotherapeutic approaches to ovarian cancer treatment
    Cariad Chester, Oliver Dorigo, Jonathan S. Berek, Holbrook E K Kohrt · 2015 · Journal for ImmunoTherapy of Cancer
18. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor
    Xiaotian Song, Qianqian Si, Rui Qi, Weidan Liu, Miao Li, Meng-Yue Guo, Lin Wei, Zhiyan Yao · 2021 · Frontiers in Immunology
19. GSH‐Responsive Metal–Organic Framework for Intratumoral Release of NO and IDO Inhibitor to Enhance Antitumor Immunotherapy
    Lihua Du, Haozhe He, Zecong Xiao, Hong Ping Xiao, Yongcheng An, Huihai Zhong, Minzhao Lin, Xiaochun Meng, Shisong Han, Xintao Shuai · 2022 · Small
20. Tryptophan metabolite 3-hydroxyanthranilic acid selectively induces activated T cell death via intracellular GSH depletion
    Sun‐Mi Lee, Young-Suk Lee, Jae-Hyeog Choi, Sae-Gwang Park, Il‐Whan Choi, Young‐Don Joo, Won-Sik Lee, Jeong-Nyeo Lee, Inhak Choi, Su‐Kil Seo · 2010 · Immunology Letters
21. Plectosphaeroic Acids A, B, and C, Indoleamine 2,3-Dioxygenase Inhibitors Produced in Culture by a Marine Isolate of the Fungus Plectosphaerella cucumerina
    Gavin Carr, Wendy Tay, Helen Bottriell, Sarah Kristin Andersen, A. Grant Mauk, Raymond J. Andersen · 2009 · Organic Letters
22. Synthesis of Indoleamine 2,3-Dioxygenase Inhibitory Analogues of the Sponge Alkaloid Exiguamine A
    Gavin Carr, Marco K. W. Chung, A. Grant Mauk, Raymond J. Andersen · 2008 · Journal of Medicinal Chemistry
23. Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals.
    Sophie S Chen, Agnieszka Michael, Simon A Butler-Manuel · 2012 · PubMed
24. The Importance of NAD in Multiple Sclerosis
    William Todd Penberthy, Ikuo Tsunoda · 2009 · Current Pharmaceutical Design
25. N-Benzyl/Aryl Substituted Tryptanthrin as Dual Inhibitors of Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase
    Dan Yang, Shengnan Zhang, Xin Fang, Leilei Guo, Nan Hu, Guo Zhanling, Xishuai Li, Shuangshuang Yang, Jin Chao He, Chunxiang Kuang et al. · 2019 · Journal of Medicinal Chemistry
26. Towards a Genetic Definition of Cancer-Associated Inflammation
    George C. Prendergast, Richard A. Metz, Alexander J. Muller · 2010 · American Journal Of Pathology
27. Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier
    Jingjing Sun, Yichao Chen, Yixian Huang, Wenchen Zhao, Yanhua Liu, Raman Venkataramanan, Binfeng Lu, Song Li · 2017 · Acta Pharmacologica Sinica
28. Targeting Mitochondrial Metabolism in Neuroinflammation: Towards a Therapy for Progressive Multiple Sclerosis
    Luca Peruzzotti‐Jametti, Stefano Pluchino · 2018 · Trends in Molecular Medicine
29. Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy
    Shu‐Yu Lin, Teng‐Kuang Yeh, Ching‐Chuan Kuo, Jen‐Shin Song, Ming-Fu Cheng, Fang-Yu Liao, Min‐Wu Chao, Han-Li Huang, Yi-Lin Chen, Chun-Yu Yang et al. · 2015 · Journal of Medicinal Chemistry
30. Untargeted metabolomics of colonic digests reveals kynurenine pathway metabolites, dityrosine and 3-dehydroxycarnitine as red versus white meat discriminating metabolites
    Caroline Rombouts, Lieselot Hemeryck, Thomas VAN HECKE, Stefaan DE SMET, Winnok Harald De Vos, Lynn Vanhaecke · 2017 · Scientific Reports
31. Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses
    Kunle O. Odunsi, Feng Qian, Amit Anand Lugade, Han Yu, Melissa Ann Geller, Steven P. Fling, Judith C. Kaiser, Andreanne M. Lacroix, Leonard D’Amico, Nirasha Ramchurren et al. · 2022 · Science Translational Medicine
32. Upregulated Expression of Indoleamine 2, 3-Dioxygenase in Primary Breast Cancer Correlates with Increase of Infiltrated Regulatory T CellsIn Situand Lymph Node Metastasis
    Jinpu Yu, Jingyan Sun, Shizhen Emily Wang, Hui Li, Shui Cao, Yizi Cong, Juntian Liu, Xiubao Ren · 2011 · Clinical and Developmental Immunology
33. Hypoxia-inducible factor-2 is essential in activating the COX2/mPGES-1/PGE2 signaling axis in colon cancer
    Xiang Xue, Yatrik Madhukar Shah · 2012 · Carcinogenesis
34. Research Progress of Indoleamine 2,3-Dioxygenase Inhibitors
    Tianze Jiang, Yingying Sun, Zhichao Yin, Sen Feng, Li‐Ping Sun, Zhiyu Li · 2015 · Future Medicinal Chemistry
35. Generation of small molecules to interfere with regulated necrosis
    Alexei Degterev, Andreas Linkermann · 2016 · Cellular and Molecular Life Sciences
36. Suppressive Influences in the Immune Response to Cancer
    Vincenzo Bronte, Simone Mocellin M. D · 2008 · Journal of Immunotherapy
37. Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy
    DONGDONG WANG, Yasushi Saga, Hiroaki Mizukami, Naoto Sato, HIROAKI NONAKA, Hiroyuki Fujiwara, Yuji Takei, 静生 町田, Osamu Takikawa, Keiya Ozawa et al. · 2011 · International Journal of Oncology
38. The Human T Cell Response to Melanoma Antigens
    Pedro J. Romero, Jean‐Charles Cerottini, Daniel E. Speiser · 2006 · Advances in immunology
39. Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors
    Florence Schramme, Stefano Crosignani, Kim Frederix, Delia Hoffmann, Luc Pilotte, Vincent Stroobant, Julie Preillon, Grégory Driessens, Benoit J. Van den Eynde · 2019 · Cancer Immunology Research
40. Tryptophan degradation in women with breast cancer: a pilot study
    Debra Lyon, Jeanne M. Walter, Angela Renee Starkweather, Christine M. Schubert, Nancy L. McCain · 2011 · BMC Research Notes
41. High expression of indoleamine 2,3-dioxygenase gene in prostate cancer
    Chantal Feder‐Mengus, Stephen Frederic Wyler, Tvrtko Hudolin, Robin Ruszat, Lukas Bubendorf, Alberto Chiarugi, Maria Gloria Pittelli, William P. Weber, Alexander Bachmann, Thomas C. Gasser et al. · 2008 · European Journal of Cancer
42. Dual-Blockade Immune Checkpoint for Breast Cancer Treatment Based on a Tumor-Penetrating Peptide Assembling Nanoparticle
    Guorui Li, Yuan Gao, Chunai Gong, Zhimin Han, Lei Qiang, Zongguang Tai, Jing Tian, Shen Gao · 2019 · ACS Applied Materials & Interfaces
43. Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy
    Sarah Elizabeth Yentz, David Carl Smith · 2018 · BioDrugs
44. Structure–activity relationship and enzyme kinetic studies on 4-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors
    Qiang Huang, Maofa Zheng, Shuangshuang Yang, Chunxiang Kuang, Cun-Jing Yu, Qing Yang · 2011 · European Journal of Medicinal Chemistry
45. Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
    Ute F. Röhrig, Somi Reddy Majjigapu, Marc Chambon, Sylvian Bron, Luc Pilotte, Didier Colau, Benoit J. Van den Eynde, Gerardo Turcatti, Pierre Vogel, Vincent Zoete et al. · 2014 · European Journal of Medicinal Chemistry
46. Genetic, Transcriptome, Proteomic, and Epidemiological Evidence for Blood-Brain Barrier Disruption and Polymicrobial Brain Invasion as Determinant Factors in Alzheimer’s Disease
    Christopher Carter · 2017 · Journal of Alzheimer s Disease Reports
47. The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase
    Rikke Bæk Sørensen, Linda Berge-Hansen, Niels Junker, Christina Aaen Hansen, Sine Reker Hadrup, Ton N. Schumacher, Inge Marie Svane, Jürgen Christian Becker, Per thor Straten, Mads Hald Andersen · 2009 · PLoS ONE
48. Immunotherapy for the Treatment of Breast Cancer
    Brenda J. Ernst, Karen S. Anderson · 2015 · Current Oncology Reports
49. Combined modality immunotherapy and chemotherapy: a new perspective
    Rupal Ramakrishnan, Scott Joseph Antonia, Dmitry I. Gabrilovich · 2008 · Cancer Immunology Immunotherapy
50. Role of tryptophan metabolism in cancers and therapeutic implications
    Xiaohan Liu, Xiao‐Yue Zhai · 2021 · Biochimie
51. Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma
    Hiroshi Urakawa, Yoshihiro Nishida, Hiroatsu Nakashima, Yoshie Shimoyama, Shigeo Nakamura, Naoki Ishiguro · 2009 · Clinical & Experimental Metastasis
52. BAR the door: Cancer suppression by amphiphysin-like genes
    Prendergast, George C., Muller, Alexander J., Ramalingam, Arivudanambi, Chang, Mee Young · 2009 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
53. Alzheimer′s Disease: APP, Gamma Secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and Their Relationships with Herpes Simplex, C. Pneumoniae , Other Suspect Pathogens, and the Immune System
    Christopher J. Carter · 2011 · International Journal of Alzheimer s Disease
54. The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer
    Yan-fang Gao, Ruiqing Peng, Jiang Li, Ya Ding, Xing Zhang, Xiaojun Wu, Zhizhong Pan, De-Sen Wan, Yi-Xin Zeng, Xiaoshi Zhang · 2009 · Journal of Translational Medicine
55. Ars Moriendi; the art of dying well – new insights into the molecular pathways of necroptotic cell death
    James M. Murphy, John Silke · 2014 · EMBO Reports
56. Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy
    Takeshi Miyazaki, Kouzo Moritake, Kazuo Yamada, Nobumasa Hara, Harumi Osago, Tomoko Shibata, Yasuhiko Akiyama, Mikako Tsuchiya · 2009 · Journal of neurosurgery
57. New Therapies in Head and Neck Cancer
    Rodell T. Santuray, Daniel E. Johnson, Jennifer Rubin Grandis · 2018 · Trends in cancer
58. Nanomedicine-based immunotherapy for central nervous system disorders
    Sumaira Hanif, Pir Muhammad, Rose Chesworth, Fawad Ur Rehman, Rongjun Qian, Meng Zheng, Bingyang Shi · 2020 · Acta Pharmacologica Sinica
59. Tumor necrosis factor α inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer
    Yu Liu, Xuemei Ji, Nannan Kang, Junfei Zhou, Xue Ya Liang, Jiaxin Li, Tianzhen Han, Chen Zhao, Tianwu Yang · 2020 · Cell Death and Disease
60. Structure–Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands
    Philipp Fronik, Isabella Poetsch, Alexander Kastner, Theresa Mendrina, Sonja Hager, Katharina Hohenwallner, Hemma Henrike Schueffl, Dietmar Herndler‐Brandstetter, Gunda Koellensperger, Evelyn Rampler et al. · 2021 · Journal of Medicinal Chemistry
61. Metabolic reprogramming in the immunosuppression of tumor-associated macrophages
    Ying Wang, Dan Wang, Li Yang, Yi Zhang · 2022 · Chinese Medical Journal
62. The Kynurenine Pathway and Indole Pathway in Tryptophan Metabolism Influence Tumor Progression
    Zhanhui Lu, Chengcheng Zhang, Jia Zhang, Wan Su, Guoying Wang, Zhongqi Wang · 2025 · Cancer Medicine
63. A high-affinity, tryptophan-selective amino acid transport system in human macrophages
    Robert L. Seymour, Vadivel Ganapathy, Andrew L. Mellor, David H. Munn · 2006 · Journal of Leukocyte Biology
64. Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer
    Josephine F. Trott, Jeffrey J. Kim, Omran Abu Aboud, Hiromi Inoue Wettersten, Benjamin J. Stewart, Grace E. Berryhill, Francisco Alejandro Uzal, Russell C. Hovey, Ching‐Hsien Chen, Katie Anderson et al. · 2016 · Oncotarget
65. The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas
    Sonner, Jana K., Deumelandt, Katrin, Ott, Martina, Thomé, Carina M., Rauschenbach, Katharina J., Schulz, Sandra, Munteanu, Bogdan, Mohapatra, Soumya, Adam, Isabell, Hofer, Ann-Cathrin et al. · 2016 · OncoImmunology
66. Targeting the Immunoregulatory Indoleamine 2,3 Dioxygenase Pathway in Immunotherapy
    Burles A Johnson rd, Babak Baban, Andrew L. Mellor · 2009 · Immunotherapy
67. Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate
    Alexander J. Muller, James B. DuHadaway, Daniel Jaller, Peter J. Curtis, Richard A. Metz, George C. Prendergast · 2010 · Cancer Research
68. Major Developments in the Design of Inhibitors along the Kynurenine Pathway
    Kelly R. Jacobs, Gloria Castellano‐González, Gilles J. Guillemin, David B. Lovejoy · 2017 · Current Medicinal Chemistry
69. 1‐L‐MT, an IDO inhibitor, prevented colitis‐associated cancer by inducing CDC20 inhibition‐mediated mitotic death of colon cancer cells
    Xiuting Liu, Wei Zhou, Xin Zhang, Yang Ding, Qianming Du, Rong Hu · 2018 · International Journal of Cancer
70. Control of the Antitumor Immune Response by Cancer Metabolism
    Charlotte Domblides, Lydia Lartigue, Benjamin Faustin · 2019 · Cells
71. Small-Molecule Targets in Immuno-Oncology
    Dashyant Dhanak, James P. Edwards, Ancho Nguyen, Peter J. Tummino · 2017 · Cell chemical biology
72. Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy
    Tianwei Weng, Xiaqiu Qiu, Jubo Wang, Zhiyu Li, Jinlei Bian · 2017 · European Journal of Medicinal Chemistry
73. Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors
    Kun Fang, Guoqiang Dong, Yu Li, Shipeng He, Ying Wu, Shanchao Wu, Wei Wang, Chunquan Sheng · 2018 · ACS Medicinal Chemistry Letters
74. Forced IDO 1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes
    Maria Teresa Pallotta, Ciriana Orabona, Roberta Bianchi, Carmine Vacca, Francesca Fallarino, Maria Laura Belladonna, Claudia Volpi, Giada Mondanelli, Marco Gargaro, M. Allegrucci et al. · 2014 · Journal of Cellular and Molecular Medicine
75. The first step of the dioxygenation reaction carried out by tryptophan dioxygenase and indoleamine 2,3-dioxygenase as revealed by quantum mechanical/molecular mechanical studies
    L. Capece, A. Lewis-Ballester, D. Batabyal, N. D. Di Russo, Syun-Ru Yeh, D. Estrin, M. Marti · 2010 · JBIC Journal of Biological Inorganic Chemistry
76. Comprehensive Analysis of the Expressionand Prognosis for TDO2 in Breast Cancer
    Qiang Liu, Jie Zhai, Xiangyi Kong, Xiangyu Wang, Zhongzhao Wang, Yi Fang, Jing Wang · 2020 · Molecular Therapy — Oncolytics
77. Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase
    Georgios Pantouris, Christopher G. Mowat · 2013 · Biochemical and Biophysical Research Communications
78. Genetic Ablation of Caveolin-1 Drives Estrogen-Hypersensitivity and the Development of DCIS-Like Mammary Lesions
    Isabelle Mercier, Mathew Craig Casimiro, Jie Zhou, Chenguang Wang, Christopher Plymire, Kelly G. Bryant, Kristin M. Daumer, Federica Sotgia, Gloria Bonuccelli, Agnieszka Katarzyna Witkiewicz et al. · 2009 · American Journal Of Pathology
79. Inhibition of Indoleamine 2,3-Dioxygenase Activity by Levo-1-Methyl Tryptophan Blocks Gamma Interferon-Induced Chlamydia trachomatis Persistence in Human Epithelial Cells
    Joyce S. A. Ibana, R. Belland, A. Zea, D. Schust, T. Nagamatsu, Yasser M. Abdelrahman, D. Tate, W. Beatty, Ashok A. Aiyar, A. Quayle · 2011 · Infection and Immunity
80. IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery
    Shan Qian, Man Zhang, Quanlong Chen, Yanying He, Wei Wang, Zhouyu Wang · 2016 · RSC Advances
81. Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor
    Aaron Balog, Tai-an Lin, Derrick Maley, Johnni L. Gullo-Brown, Enzo Hamza Kandoussi, Jianing Zeng, John T. Hunt · 2020 · Molecular Cancer Therapeutics
82. The role of indoleamine 2,3-dioxygenase in transplantation
    Ursula Hainz, Birgit Jürgens, Andreas Heitger · 2006 · Transplant International
83. Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity
    Henri‐Alexandre Michaud, Jean‐François Eliaou, Virginie Lafont, Nathalie Bonnefoy, Laurent Gros · 2014 · OncoImmunology
84. Context Drives Diversification of Monocytes and Neutrophils in Orchestrating the Tumor Microenvironment
    Juhee Jeong, Yoorock Suh, Keehoon Jung · 2019 · Frontiers in Immunology
85. From (Tool)Bench to Bedside: The Potential of Necroptosis Inhibitors
    Christopher R. Gardner, Katherine A. Davies, Ying Zhang, Martin Brzozowski, Peter E. Czabotar, James M. Murphy, Guillaume Lessène · 2023 · Journal of Medicinal Chemistry
86. Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway
    Martina Ott, Ulrike M. Litzenburger, Katharina J. Rauschenbach, Lukas Bunse, Katharina Ochs, Felix Sahm, Stefan Pusch, Christiane A. Opitz, Jonas Blaes, Andreas von Deimling et al. · 2014 · Glia
87. Emerging Targets in Cancer Immunotherapy: Beyond CTLA-4 and PD-1
    Amer Assal, Justin D. Kaner, Gopichand Pendurti, Xingxing Zang · 2015 · Immunotherapy
88. Pharmacological Inhibition of Indoleamine 2,3-Dioxygenase-2 and Kynurenine 3-Monooxygenase, Enzymes of the Kynurenine Pathway, Significantly Diminishes Neuropathic Pain in a Rat Model
    E. Rojewska, Katarzyna Ciapała, A. Piotrowska, W. Makuch, J. Mika · 2018 · Frontiers in Pharmacology
89. Molecular docking and dynamic simulation studies evidenced plausible immunotherapeutic anticancer property by Withaferin A targeting indoleamine 2,3-dioxygenase
    S. V. G. Reddy, K. Thammi Reddy, V. Valli Kumari, Syed Hussain Basha · 2015 · Journal of Biomolecular Structure and Dynamics
90. Dual Functional Immunostimulatory Polymeric Prodrug Carrier with Pendent Indoximod for Enhanced Cancer Immunochemotherapy
    Zhuoya Wan, Jingjing Sun, Jieni Xu, Pearl Moharil, Jing Chen, Junchi Xu, Junjie Zhu, Jiang Li, Yixian Huang, Pengfei Xu et al. · 2019 · SSRN Electronic Journal
91. Inhibitors of human indoleamine 2,3‐dioxygenase identified with a target‐based screen in yeast
    Eduardo Vottero, Aruna D. Balgi, Kate Woods, Stuart Tugendreich, Teri Mélèse, Raymond J. Andersen, A. Grant Mauk, Michel Roberge · 2006 · Biotechnology Journal
92. 1-l-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-d-methyltryptophan
    Hajime Julie Yuasa, Helen J. Ball, Christopher Austin, Nicholas Henry Hunt · 2010 · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology
93. Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2
    Supun M. Bakmiwewa, Amos A. Fatokun, Anh Tran, Richard J. Payne, Nicholas Henry Hunt, Helen J. Ball · 2012 · Bioorganic & Medicinal Chemistry Letters
94. Targeting tumour-associated macrophages
    Antonio Sica, Luca Rubino, Alessandra Mancino, Paola Larghi, Chiara Porta, Monica Rimoldi, Graziella Solinas, Massimo Locati, Paola Allavena, Alberto Mantovani · 2007 · Expert Opinion on Therapeutic Targets
95. Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder
    Nicholas W. S. Davies, Gilles J. Guillemin, Bruce James Brew · 2010 · International Journal of Tryptophan Research
96. Immune Signatures of Murine and Human Cancers Reveal Unique Mechanisms of Tumor Escape and New Targets for Cancer Immunotherapy
    Rebecca E. Sadun, Suzanne M. Sachsman, Xiaoying Chen, K. Christenson, William Z. Morris, Peisheng Hu, Alan L. Epstein · 2007 · Clinical Cancer Research
97. Resistance Exercise Reduces Kynurenine Pathway Metabolites in Breast Cancer Patients Undergoing Radiotherapy
    Philipp Zimmer, Martina E. Schmidt, Mirja Tamara Prentzell, Bianca Berdel, Joachim Wiskemann, Karl Heinz Kellner, Jürgen Debus, Cornelia M. Ulrich, Christiane A. Opitz, Karen Steindorf · 2019 · Frontiers in Oncology
98. Induction of Kidney Allograft Tolerance by Soluble CD83 Associated With Prevalence of Tolerogenic Dendritic Cells and Indoleamine 2,3-Dioxygenase
    Zhu Lan, Wei Ge, Jacqueline Arp, Jifu Jiang, Weihua Liu, Dina Gordon, Don G. Healey, Mark A. Debenedette, Charles A. Nicolette, Bertha M Garcia et al. · 2010 · Transplantation
99. Metformin suppresses CYP1A1 and CYP1B1 expression in breast cancer cells by down-regulating aryl hydrocarbon receptor expression
    Minh Truong, Hyung Gyun Kim, Thi Thu Phuong Tran, Tilak Khanal, Jae Ho Choi, Young‐Chul Chung, Tae Cheon Jeong, Hye Gwang Jeong · 2014 · Toxicology and Applied Pharmacology
100. The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies
     Hamed Hosseinalizadeh, Mehrdad Mahmoodpour, Ali Akbar Samadani, Mehryar Habibi Roudkenar · 2022 · Medical Oncology